Estatísticas Básicas
| CIK | 1513525 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Adial Pharmaceuticals, Inc.
SEC Filings (Chronological Order)
Esta página fornece uma lista completa e cronológica de Arquivamentos da SEC, excluindo os arquivamentos de propriedade que fornecemos em outro lugar.
| May 11, 2026 |
Adial Pharmaceuticals Reports 2026 First Quarter Financial Results and Provides Business Update Exhibit 99.1 Adial Pharmaceuticals Reports 2026 First Quarter Financial Results and Provides Business Update Glen Allen, VA – May 11, 2026 – Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reporte |
|
| May 11, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 11, 2026 Adial Pharmaceuticals, Inc. (Exact name of registrant as specified in charter) Delaware (State or other jurisdiction of incorporation) 001-38323 82-3074668 (Commission Fi |
|
| May 8, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38323 ADIAL PHARMACEUTICAL |
|
| April 9, 2026 |
FORM OF ADIAL PHARMACEUTICALS, INC. RESTRICTED STOCK AWARD AGREEMENT Exhibit 10.1 FORM OF ADIAL PHARMACEUTICALS, INC. RESTRICTED STOCK AWARD AGREEMENT This Restricted Stock Award Agreement (this “Agreement”), dated as of the “Award Date” set forth in the attached Exhibit A, is entered into between Adial Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the individual identified in Exhibit A (the “Awardee”). Capitalized terms that are not otherwise |
|
| April 9, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 7, 2026 Adial Pharmaceuticals, Inc. (Exact name of registrant as specified in charter) Delaware (State or other jurisdiction of incorporation) 001-38323 82-3074668 (Commission F |
|
| March 6, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 6, 2026 Adial Pharmaceuticals, Inc. (Exact name of registrant as specified in charter) Delaware (State or other jurisdiction of incorporation) 001-38323 82-3074668 (Commission F |
|
| March 6, 2026 |
Adial Pharmaceuticals Reports 2025 Fiscal Year Financial Results and Provides Business Update Exhibit 99.1 Adial Pharmaceuticals Reports 2025 Fiscal Year Financial Results and Provides Business Update Glen Allen, VA – March 6, 2026 – Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported |
|
| March 5, 2026 |
Exhibit 4.17 DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED The capital stock of Adial Pharmaceuticals, Inc. (“we,” “us,” and “our”) registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) consists of Common Stock, par value $0.001 per share(the “Common Stock”). Description of Common Stock G |
|
| March 5, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38323 ADIAL PHARMACEUTICALS, INC. |
|
| March 3, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 26, 2026 Adial Pharmaceuticals, Inc. (Exact name of registrant as specified in charter) Delaware (State or other jurisdiction of incorporation) 001-38323 82-3074668 (Commissi |
|
| March 3, 2026 |
Exhibit 99.1 Adial Pharmaceuticals Signs an Exclusive AD04 Collaboration Framework with Molteni Farmaceutici for Europe which Anticipates Nearly $60 Million in Potential Royalties and Milestones upon execution of a Definitive Agreement The Collaboration Framework marks Adial’s first step towards commercial partnership and establishing an exclusive European pathway as AD04 advances toward pivotal P |
|
| February 24, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 23, 2026 Adial Pharmaceuticals, Inc. (Exact name of registrant as specified in charter) Delaware (State or other jurisdiction of incorporation) 001-38323 82-3074668 (Commissi |
|
| February 24, 2026 |
Exhibit 99.1 Adial Pharmaceuticals Regains Full Compliance with Nasdaq Listing Requirement Company Highlights Advanced Partnering Discussions as AD04 Advances Toward Phase 3 GLEN ALLEN, Va., February 24, 2026 — Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addicti |
|
| February 4, 2026 |
CERTIFICATE OF AMENDMENT to the CERTIFICATE OF INCORPORATION OF ADIAL PHARMACEUTICALS, INC. Exhibit 3.1 CERTIFICATE OF AMENDMENT to the CERTIFICATE OF INCORPORATION OF ADIAL PHARMACEUTICALS, INC. Adial Pharmaceuticals, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, does hereby certify that: 1. The name of the Corporation is Adial Pharmaceuticals, Inc. 2. The Board of Directors of the Corporation |
|
| February 4, 2026 |
Exhibit 99.1 Adial Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid Price Requirement Common Stock Will Begin Trading on Split-Adjusted Basis on February 6, 2026 GLEN ALLEN, Va. – February 3, 2026 – Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the tre |
|
| February 4, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 3, 2026 Adial Pharmaceuticals, Inc. (Exact name of registrant as specified in charter) Delaware (State or other jurisdiction of incorporation) 001-38323 82-3074668 (Commissio |
|
| January 6, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| January 6, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): January 5, 2026 Adial Pharmaceuticals, Inc. (Exact name of registrant as specified in charter) Delaware (State or other jurisdiction of incorporation) 001-38323 82-3074668 (Commission |
|
| December 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| December 19, 2025 |
Up to 13,823,512 Shares of Common Stock PROSPECTUS Filed Pursuant to Rule 424(b)(5) Registration No. 333-292110 Up to 13,823,512 Shares of Common Stock This prospectus relates to the resale from time to time of up to 13,823,512 shares of common stock, par value $0.001 per share (the “Common Stock”), of Adial Pharmaceuticals, Inc. by the Selling Stockholder identified in this prospectus (the “Selling Stockholder”), including its pledgees |
|
| December 15, 2025 |
Adial Pharmaceuticals, Inc. 4870 Sadler Road, Suite 300 Glen Allen, Virginia 23060 (310) 988-0643 Adial Pharmaceuticals, Inc. 4870 Sadler Road, Suite 300 Glen Allen, Virginia 23060 (310) 988-0643 December 15, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Jason Drury Re: Adial Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed on December 12, 2025 File No: 333-292110 Request For Ac |
|
| December 12, 2025 |
As filed with the Securities and Exchange Commission on December 12, 2025 As filed with the Securities and Exchange Commission on December 12, 2025 Registration No. |
|
| December 12, 2025 |
Ex-Filing Fees CALCULATION OF FILING FEE TABLES S-3 Adial Pharmaceuticals, Inc. Table 1: Newly Registered and Carry Forward Securities Line Item Type Security Type Security Class Title Notes Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securities Fees to be Paid Equity Common St |
|
| December 1, 2025 |
Exhibit 99.1 Adial Pharmaceuticals Announces a Warrant Inducement Transaction for Approximately $2.86 Million in Gross Proceeds GLEN ALLEN, VA, November 26, 2025 (GLOBE NEWSWIRE) – Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, toda |
|
| December 1, 2025 |
Adial Pharmaceuticals, Inc. 4870 Sadler Road, Ste 300 Glen Allen, Virginia 23060 Exhibit 10.1 Adial Pharmaceuticals, Inc. 4870 Sadler Road, Ste 300 Glen Allen, Virginia 23060 November 25, 2025 To the Holder of Series C-1 Common Stock Purchase Warrants Issued on May 5, 2025 and Series E Common Stock Purchase Warrants Issued on June 18, 2025 Re: Inducement Offer to Exercise Existing Shares of Common Stock Purchase Warrants Dear Holder: Adial Pharmaceuticals, Inc. (the “Company”) |
|
| December 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 25, 2025 Adial Pharmaceuticals, Inc. (Exact name of registrant as specified in charter) Delaware 001-38323 82-3074668 (State or other jurisdiction of incorporation) (Commissi |
|
| December 1, 2025 |
FORM OF SERIES F COMMON STOCK PURCHASE WARRANT Adial Pharmaceuticals, Inc. Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| November 14, 2025 |
Adial Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update Exhibit 99.1 Adial Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update Glen Allen, VA – November 14, 2025 – Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and re |
|
| November 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 14, 2025 Adial Pharmaceuticals, Inc. (Exact name of registrant as specified in charter) Delaware 001-38323 82-3074668 (State or other jurisdiction of incorporation) (Commissi |
|
| November 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38323 ADIAL PHARMACEUT |
|
| September 16, 2025 |
Exhibit 99.1 Adial Pharmaceuticals Provides Business Update following Favorable Comments from FDA End-of-Phase 2 (EOP2) Meeting for AD04 FDA Minutes Reflect Constructive Dialogue and Successful Meeting Outcome with Alignment on Upcoming Phase 3 Clinical Trial Design for AD04 In Alcohol Use Disorder Glen Allen, VA – September 16, 2025 – Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Co |
|
| September 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): September 16, 2025 Adial Pharmaceuticals, Inc. (Exact name of registrant as specified in charter) Delaware (State or other jurisdiction of incorporation) 001-38323 82-3074668 (Commiss |
|
| September 9, 2025 |
Ex-Filing Fees CALCULATION OF FILING FEE TABLES S-8 ADIAL PHARMACEUTICALS, INC. Table 1: Newly Registered and Carry Forward Securities Line Item Type Security Type Security Class Title Notes Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securities Fees to be Paid Equity Common St |
|
| September 9, 2025 |
As filed with the Securities and Exchange Commission on September 9, 2025 As filed with the Securities and Exchange Commission on September 9, 2025 Registration No. |
|
| September 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): September 2, 2025 Adial Pharmaceuticals, Inc. (Exact name of registrant as specified in charter) Delaware 001-38323 82-3074668 (State or other jurisdiction of incorporation) (Commissi |
|
| September 3, 2025 |
Exhibit 99.1 Adial Pharmaceuticals Granted a 180 Calendar Day Extension by Nasdaq to Regain Compliance with the Minimum Bid Price Rule GLEN ALLEN, Va., September 3, 2025 — Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announc |
|
| August 14, 2025 |
Adial Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update Èxhibit 99.1 Adial Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update Glen Allen, VA – August 14, 2025 – Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and rep |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 14, 2025 Adial Pharmaceuticals, Inc. (Exact name of registrant as specified in charter) Delaware 001-38323 82-3074668 (State or other jurisdiction of incorporation) (Commission |
|
| August 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38323 ADIAL PHARMACEUTICALS |
|
| August 1, 2025 |
Exhibit 1.1 ADIAL PHARMACEUTICALS, INC.COMMON STOCK SALES AGREEMENT August 1, 2025 A.G.P./Alliance Global Partners 590 Madison Avenue New York, NY 10022 Ladies and Gentlemen: Adial Pharmaceuticals, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with A.G.P./Alliance Global Partners (the “Sales Agent”), as follows: 1. Issuance and Sale of Shares. The Company |
|
| August 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 1, 2025 Adial Pharmaceuticals, Inc. (Exact name of registrant as specified in charter) Delaware 001-38323 82-3074668 (State or other jurisdiction of incorporation) (Commission |
|
| August 1, 2025 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT OF CERTIFICATE OF INCORPORATION OF ADIAL PHARMACEUTICALS, INC. Adial Pharmaceuticals, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, does hereby certify that: 1. The name of the Corporation is Adial Pharmaceuticals, Inc. 2. The Board of Directors of the Corporation has |
|
| August 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 31, 2025 Adial Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-38323 82-3074668 (State or other jurisdiction of Incorporation or organiz |
|
| August 1, 2025 |
Amendment No. 7 to the Adial Pharmaceuticals, Inc. 2017 Equity Incentive Plan Exhibit 10.1 AMENDMENT NO. 7 TO THE ADIAL PHARMACEUTICALS, INC. 2017 EQUITY INCENTIVE PLAN This amendment (the “Amendment”) to the Adial Pharmaceuticals, Inc. 2017 Equity Incentive Plan (the “Plan”), is hereby adopted this 1st day of August, 2025, by Adial Pharmaceuticals, Inc. (the “Company”). All capitalized terms used in this Amendment and not otherwise defined herein shall have the meanings se |
|
| August 1, 2025 |
Up to $4,983,000 of Shares of Common Stock ADIAL PHARMACEUTICALS, INC. Filed Pursuant to Rule 424(b)(5) Registration No. 333-276496 PROSPECTUS SUPPLEMENT (To prospectus dated January 24, 2024) Up to $4,983,000 of Shares of Common Stock ADIAL PHARMACEUTICALS, INC. We have entered into a sales agreement with A.G.P./Alliance Global Partners (“A.G.P.” or “the Sales Agent”), dated August 1, 2025 (the “Sales Agreement”), relating to the sale of shares of our common stock, |
|
| July 31, 2025 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-276496 PROSPECTUS SUPPLEMENT (To prospectus dated January 24, 2024) ADIAL PHARMACEUTICALS, INC. This prospectus supplement amends and supplements the information in the prospectus, dated April 18, 2024 (the “Prior Prospectus”), filed with the Securities and Exchange Commission as a part of the Adial Pharmaceutical, Inc. (“we”, “us” or “our”) re |
|
| July 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 14, 2025 Adial Pharmaceuticals, Inc. (Exact name of registrant as specified in charter) Delaware (State or other jurisdiction of incorporation) 001-38323 82-3074668 (Commission F |
|
| July 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 9, 2025 Adial Pharmaceuticals, Inc. (Exact name of registrant as specified in charter) Delaware (State or other jurisdiction of incorporation) 001-38323 82-3074668 (Commission Fi |
|
| June 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6 (e)(2)) ☒ Def |
|
| June 18, 2025 |
Exhibit 1.1 June 16, 2025 Adial Pharmaceuticals, Inc. 4870 Sadler Road, Ste 300 Glen Allen, Virginia 23060 Dear Mr. Claiborne: Subject to the terms and conditions of this letter agreement (the “Agreement”) between A.G.P./Alliance Global Partners (the “Placement Agent”), as the sole placement agent, and Adial Pharmaceuticals, Inc., a Delaware corporation (the “Company”), the parties hereby agree th |
|
| June 18, 2025 |
Exhibit 4.2 SERIES E COMMON STOCK PURCHASE WARRANT Adial Pharmaceuticals, Inc. Warrant Shares: Issue Date: June 18, 2025 THIS SERIES E COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Stockholder |
|
| June 18, 2025 |
Form of Securities Purchase Agreement, dated June 17, 2025 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of June 17, 2025, between Adial Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditi |
|
| June 18, 2025 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-287826 Prospectus ADIAL PHARMACEUTICALS, INC. 5,341,200 Shares of Common Stock Pre-Funded Warrants to Purchase up to 5,758,800 Shares of Common Stock Series D Warrants to Purchase up to 11,100,000 Shares of Common Stock Series E Warrants to Purchase up to 8,325,000 Shares of Common Stock 25,183,800 Shares of Common Stock Issuable Upon Exercise |
|
| June 18, 2025 |
Exhibit 4.1 SERIES D COMMON STOCK PURCHASE WARRANT Adial Pharmaceuticals, Inc. Warrant Shares: Issue Date: June 18, 2025 THIS SERIES D COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Stockholder |
|
| June 18, 2025 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 16, 2025 Adial Pharmaceuticals, Inc. (Exact name of registrant as specified in charter) Delaware 001-38323 82-3074668 (State or other jurisdiction of incorporation) (Commission F |
|
| June 18, 2025 |
Adial Pharmaceuticals Announces Pricing of $3.6 Million Public Offering Exhibit 99.1 Adial Pharmaceuticals Announces Pricing of $3.6 Million Public Offering GLEN ALLEN, Va., June 17, 2025 (GLOBE NEWSWIRE) — Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced the pricing of its “reasonable bes |
|
| June 18, 2025 |
Exhibit 10.2 AMENDMENT NO. 1 TO SERIES B-1 COMMON STOCK PURCHASE WARRANT AND SERIES C-1 COMMON STOCK PURCHASE WARRANT This AMENDMENT TO THE SERIES B-1 COMMON STOCK PURCHASE WARRANT and SERIES C-1 COMMON STOCK PURCHASE WARRANT (this “Amendment”) is entered into as of June 17, 2025, by and between Adial Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Armistice Capital Master Fund |
|
| June 18, 2025 |
Exhibit 4.3 PRE-FUNDED COMMON STOCK PURCHASE WARRANT Adial Pharmaceuticals, Inc. Warrant Shares: Issue Date: June 18, 2025 Initial Exercise Date: June 18, 2025 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, |
|
| June 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6 (e)(2)) ☐ Def |
|
| June 16, 2025 |
Other Events, Shareholder Director Nominations UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 16, 2025 Adial Pharmaceuticals, Inc. (Exact name of registrant as specified in charter) Delaware 001-38323 82-3074668 (State or other jurisdiction of incorporation) (Commission F |
|
| June 13, 2025 |
As filed with the Securities and Exchange Commission on June 13, 2025. As filed with the Securities and Exchange Commission on June 13, 2025. Registration No. 333-287826 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ADIAL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 8071 82-3074668 (State or other jurisdiction of incor |
|
| June 12, 2025 |
June 12, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| June 12, 2025 |
June 12, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| June 10, 2025 |
Up to 6,730,376 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-287679 PROSPECTUS Up to 6,730,376 Shares of Common Stock This prospectus relates to the resale from time to time of up to 6,730,376 shares of common stock, par value $0.001 per share (the “Common Stock”), of Adial Pharmaceuticals, Inc. by the Selling Stockholders identified in this prospectus (the “Selling Stockholders”), including their pledge |
|
| June 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6 (e)(2)) ☒ Definitive Proxy Stat |
|
| June 10, 2025 | ||
| June 6, 2025 |
Exhibit 4.23 SERIES D COMMON STOCK PURCHASE WARRANT Adial Pharmaceuticals, Inc. Warrant Shares: Issue Date:, 2025 THIS SERIES D COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the earlier of (i) if p |
|
| June 6, 2025 |
As filed with the Securities and Exchange Commission on June 6, 2025. As filed with the Securities and Exchange Commission on June 6, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ADIAL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 8071 82-3074668 (State or other jurisdiction of incorporation or organization) |
|
| June 6, 2025 |
Exhibit 1.1 [], 2025 Adial Pharmaceuticals, Inc. 4870 Sadler Road, Ste 300 Glen Allen, Virginia 23060 Dear Mr. Claiborne: Subject to the terms and conditions of this letter agreement (the “Agreement”) between A.G.P./Alliance Global Partners (the “Placement Agent”), as the sole placement agent, and Adial Pharmaceuticals, Inc., a Delaware corporation (the “Company”), the parties hereby agree that th |
|
| June 6, 2025 |
Exhibit 4.24 SERIES E COMMON STOCK PURCHASE WARRANT Adial Pharmaceuticals, Inc. Warrant Shares: Issue Date:, 2025 THIS SERIES E COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the earlier of (i) if p |
|
| June 6, 2025 |
Form of Securities Purchase Agreement Exhibit 10.48 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of [], 2025, between Adial Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions |
|
| June 6, 2025 |
Exhibit 107 Calculation of Filing Fee Table Form S-1 (Form Type) Adial Pharmaceuticals, Inc. |
|
| June 6, 2025 |
Exhibit 4.25 PRE-FUNDED COMMON STOCK PURCHASE WARRANT Adial Pharmaceuticals, Inc. Warrant Shares: Issue Date:, 2025 Initial Exercise Date: , 2025 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time o |
|
| June 6, 2025 |
June 6, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| June 5, 2025 |
June 5, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| June 4, 2025 |
June 4, 2025 Cary Claiborne Chief Executive Officer Adial Pharmaceuticals, Inc. 4870 Sadler Road, Suite 300 Glen Allen, VA 23060 Re: Adial Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed May 30, 2025 File No. 333-287679 Dear Cary Claiborne: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding req |
|
| May 30, 2025 |
Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Adial Pharmaceuticals, Inc. |
|
| May 30, 2025 |
Exhibit 4.21 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| May 30, 2025 |
Exhibit 4.20 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| May 30, 2025 |
As filed with the Securities and Exchange Commission on May 30, 2025 As filed with the Securities and Exchange Commission on May 30, 2025 Registration No. |
|
| May 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 23, 2025 Adial Pharmaceuticals, Inc. (Exact name of registrant as specified in charter) Delaware (State or other jurisdiction of incorporation) 001-38323 82-3074668 (Commission Fi |
|
| May 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6 (e)(2)) ☐ Definitive Proxy Stat |
|
| May 15, 2025 |
Adial Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update Exhibit 99.1 Adial Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update Glen Allen, VA – May 15, 2025 – Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reporte |
|
| May 15, 2025 |
Financial Statements and Exhibits, Other Events, Shareholder Director Nominations UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 14, 2025 Adial Pharmaceuticals, Inc. (Exact name of registrant as specified in charter) Delaware 001-38323 82-3074668 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 15, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 15, 2025 Adial Pharmaceuticals, Inc. (Exact name of registrant as specified in charter) Delaware 001-38323 82-3074668 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38323 ADIAL PHARMACEUTICAL |
|
| May 7, 2025 |
EXHIBIT 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| May 7, 2025 |
Adial Pharmaceuticals Announces a Warrant Inducement Transaction for $2.75 Million in Gross Proceeds EXHIBIT 99.1 Adial Pharmaceuticals Announces a Warrant Inducement Transaction for $2.75 Million in Gross Proceeds GLEN ALLEN, Va., May 02, 2025 — Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced its entry into a warran |
|
| May 7, 2025 |
EXHIBIT 10.1 Adial Pharmaceuticals, Inc. 4870 Sadler Road, Ste 300 Glen Allen, Virginia 23060 May , 2025 To the Holder of Series C Common Stock Purchase Warrants Issued on March 6, 2024 and Series B Common Stock Purchase Warrants Issued on October 24, 2023 Re: Inducement Offer to Exercise Existing Shares of Common Stock Purchase Warrants Dear Holder: Adial Pharmaceuticals, Inc. (the “Company”) is |
|
| May 7, 2025 |
EXHIBIT 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| May 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 2, 2025 Adial Pharmaceuticals, Inc. (Exact name of registrant as specified in charter) Delaware 001-38323 82-3074668 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 2, 2025 |
2,369,000 Shares of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-278652 PROSPECTUS SUPPLEMENT (To Prospectus dated April 19, 2024) 2,369,000 Shares of Common Stock This prospectus supplement updates, supersedes and amends certain information contained in the prospectus dated April 19, 2024 (the “Original Prospectus”) relating to the resale from time to time of up to an aggregate of 2,369,000 shares of common |
|
| May 2, 2025 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-275397 PROSPECTUS SUPPLEMENT (To Prospectus dated November 16, 2023) 4,340,426 Shares Common Stock This prospectus supplement updates, supersedes and amends certain information contained in the prospectus dated November 16, 2023 (the “Original Prospectus”) relating to the resale from time to time of up to 4,340,426 shares of common stock, par v |
|
| May 1, 2025 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 28, 2025 Adial Pharmaceuticals, Inc. (Exact name of registrant as specified in charter) Delaware 001-38323 82-3074668 (State or other jurisdiction of incorporation) (Commission |
|
| May 1, 2025 |
Letter from Marcum LLP, dated May 1, 2025, addressed to the Securities and Exchange Commission Exhibit 16.1 May 1, 2025 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read the statements made by Adial Pharmaceuticals, Inc. under Item 4.01 of its Form 8-K dated April 28, 2025. We agree with the statements concerning our Firm in such Form 8-K; we are not in a position to agree or disagree with other statements of Adial Pharmaceuticals, Inc. c |
|
| April 1, 2025 |
April 1, 2025 Vinay Shah Chief Financial Officer Adial Pharmaceuticals, Inc. 4870 Sadler Road, Ste 300 Glen Allen, VA 23060 Re: Adial Pharmaceuticals, Inc. Draft Registration Statement on Form S-1 Submitted March 27, 2025 CIK No. 0001513525 Dear Vinay Shah: This is to advise you that we do not intend to review your registration statement. We request that you publicly file your registration stateme |
|
| March 27, 2025 |
Phone: (212) 885-5358 Fax: (917) 332-3824 Email: [email protected] March 27, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Adial Pharmaceuticals, Inc. Draft Registration Statement (DRS) on Form S-1 Submitted on March 27, 2025 CIK No. 0001513525 Dear Sir or Madam: On behalf of our client, Adial |
|
| March 27, 2025 |
As confidentially submitted on March 27, 2025 to the Securities and Exchange Commission. |
|
| March 21, 2025 |
Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) is entered into as of April 1, 2025 (the “Effective Date”) by and between Adial Pharmaceuticals, Inc., a Delaware corporation, (the “Company”), and Tony Goodman (the “Executive”). Recitals WHEREAS, the Company desires to employ the Executive as the Chief Operating Officer of the Company and the Executive desires to acce |
|
| March 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 20, 2025 Adial Pharmaceuticals, Inc. (Exact name of registrant as specified in charter) Delaware (State or other jurisdiction of incorporation) 001-38323 82-3074668 (Commission |
|
| March 7, 2025 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 5, 2025 Adial Pharmaceuticals, Inc. (Exact name of registrant as specified in charter) Delaware (State or other jurisdiction of incorporation) 001-38323 82-3074668 (Commission F |
|
| March 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 4, 2025 Adial Pharmaceuticals, Inc. (Exact name of registrant as specified in charter) Delaware 001-38323 82-3074668 (State or other jurisdiction of incorporation) (Commission F |
|
| March 4, 2025 |
Adial Pharmaceuticals Reports 2024 Fiscal Year Financial Results and Provides Business Update Exhibit 99.1 Adial Pharmaceuticals Reports 2024 Fiscal Year Financial Results and Provides Business Update Glen Allen, VA – March 4, 2025 – Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported |
|
| March 4, 2025 |
Exhibit 19.1 ADIAL PHARMACEUTICALS, INC. Insider Trading Policy 1. Purpose. Both the Securities and Exchange Commission (the "SEC") and Congress are very concerned about maintaining the fairness and integrity of the U.S. capital markets. The securities laws are continually reviewed and amended to prevent people from taking advantage of "inside information" and to increase the punishment for those |
|
| March 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38323 ADIAL PHARMACEUTICALS, INC. |
|
| February 25, 2025 |
Exhibit 99.1 Adial Pharmaceuticals Receives Positive Response from FDA Meeting Regarding Proposed In Vitro Bridging Strategy for AD04 FDA feedback confirms Adial’s proposed in vitro bridging strategy to the Phase 3 formulation to fulfill the bridging requirement for the 505(b)(2) regulatory registration pathway for approval Adial moves forward with manufacturing of clinical supplies for upcoming P |
|
| February 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 25, 2025 Adial Pharmaceuticals, Inc. (Exact name of registrant as specified in charter) Delaware (State or other jurisdiction of incorporation) 001-38323 82-3074668 (Commissi |
|
| January 13, 2025 |
Business Development Presentation of Adial Pharmaceuticals, Inc., dated January 2025 Exhibit 99.1 |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): January 13, 2025 Adial Pharmaceuticals, Inc. (Exact name of registrant as specified in charter) Delaware (State or other jurisdiction of incorporation) 001-38323 82-3074668 (Commissio |
|
| January 8, 2025 |
Exhibit 99.1 December 2021 CONFIDENTIAL Medicines f or A ddi c tion Investor Presentation January 2025 This presentation includes statements that are, or may be deemed, ‘‘forward - looking statements . ’’ In some cases, these forward - looking statements can be identified by the use of forward - looking terminology, including the terms “believes,” “might,” estimates,” “approximately,” “expects,” “ |
|
| January 8, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): January 8, 2025 Adial Pharmaceuticals, Inc. (Exact name of registrant as specified in charter) Delaware (State or other jurisdiction of incorporation) 001-38323 82-3074668 (Commission |
|
| December 31, 2024 |
Up to 5,000,000 Shares of Common Stock 424B3 1 ea0226362-424b3adialpharma.htm PROSPECTUS Filed Pursuant to Rule 424(b)(3) PROSPECTUS Registration No. 333-283968 Up to 5,000,000 Shares of Common Stock This prospectus relates to the offering and resale by Alumni Capital LP (“Alumni Capital” or the “Selling Stockholder”) of up to 5,000,000 shares (the “Shares”) of our common stock, par value $0.001 per share (the “Common Stock”), which in |
|
| December 26, 2024 |
December 26, 2024 Cary Claiborne President and Chief Executive Officer Adial Pharmaceuticals, Inc. |
|
| December 26, 2024 |
December 26, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| December 20, 2024 |
As filed with the Securities and Exchange Commission on December 20, 2024 As filed with the Securities and Exchange Commission on December 20, 2024 Registration No. |
|
| December 20, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-1 (Form Type) Adial Pharmaceuticals, Inc. |
|
| December 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): December 13, 2024 Adial Pharmaceuticals, Inc. (Exact name of registrant as specified in charter) Delaware (State or other jurisdiction of incorporation) 001-38323 82-3074668 (Commissi |
|
| December 18, 2024 |
Exhibit 10.2 TERMINATION AGREEMENT THIS TERMINATION AGREEMENT (this “Termination Agreement”), dated as of December 13, 2024 (the “Effective Date”), is entered into by and between ADIAL PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and ALUMNI CAPITAL LP, a Delaware limited partnership (the “Investor”). RECITALS WHEREAS, the Company and the Investor have entered into a new Purchase |
|
| December 18, 2024 |
Exhibit 10.1 PURCHASE AGREEMENT THIS PURCHASE AGREEMENT (the “Agreement”), dated as of December 13, 2024 (the “Execution Date”), is entered into by and between ADIAL PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and ALUMNI CAPITAL LP, a Delaware limited partnership (the “Investor”). RECITALS WHEREAS, Subject to the terms and conditions set forth in this Agreement, the Company wish |
|
| December 12, 2024 |
As filed with the Securities and Exchange Commission on December 12, 2024 As filed with the Securities and Exchange Commission on December 12, 2024 Registration No. |
|
| December 12, 2024 |
Exhibit 107 Calculation of Filing Fee Tables S-8 (Form Type) Adial Pharmaceuticals, Inc. |
|
| December 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): December 5, 2024 Adial Pharmaceuticals, Inc. (Exact name of registrant as specified in charter) Delaware (State or other jurisdiction of incorporation) 001-38323 82-3074668 (Commissio |
|
| December 6, 2024 |
Exhibit 10.1 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Agreement”) between Adial Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Cary Claiborne (the “Executive”) is effective as of December 5, 2024 (the “Effective Date”) and replaces and supersedes the employment agreement between the Executive and the Company, December 7, 202 |
|
| November 18, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 14, 2024 Adial Pharmaceuticals, Inc. (Exact name of registrant as specified in charter) Delaware (State or other jurisdiction of incorporation) 001-38323 82-3074668 (Commissi |
|
| November 18, 2024 |
Exhibit 99.1 Adial Pharmaceuticals Announces Positive Topline Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder Confirmed relative bioavailability to the reference standard, dose proportional increases in pharmacokinetic exposure, and no food effect Marks final study needed for the upcoming FDA meeting for the Phase 3 study design and ongoing partne |
|
| November 14, 2024 |
ADIL / Adial Pharmaceuticals, Inc. / ARMISTICE CAPITAL, LLC Passive Investment SC 13G/A 1 armistice-adil093024a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1 )* ADIAL PHARMACEUTICALS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 00688A205 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box |
|
| November 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38323 ADIAL PHARMACEUT |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 12, 2024 Adial Pharmaceuticals, Inc. (Exact name of registrant as specified in charter) Delaware 001-38323 82-3074668 (State or other jurisdiction of incorporation) (Commissi |
|
| November 12, 2024 |
Exhibit 10.1 AMENDMENT NO. 6 TO THE ADIAL PHARMACEUTICALS, INC. 2017 EQUITY INCENTIVE PLAN This amendment (the “Amendment”) to the Adial Pharmaceuticals, Inc. 2017 Equity Incentive Plan (the “Plan”), is hereby adopted as of November 12, 2024, by the Board of Directors (the “Board”) of Adial Pharmaceuticals, Inc. (the “Company”). All capitalized terms used in this Amendment and not otherwise define |
|
| November 5, 2024 |
Exhibit 10.1 4870 Sadler Road, Ste 300 Glen Allen, VA 23060 USA +1.804.487.8196 www.adialpharma.com VIA FEDEX AND U.S. MAIL November 1, 2024 Personal and Confidential Joseph Truluck 1534A Wilhelmina Rise Honolulu, HI 96816 Re: Separation and Release Dear Joe: This letter follows up our discussion concerning your resignation of your position with Adial Pharmaceuticals, Inc. (the “Company”). In reco |
|
| November 5, 2024 |
Adial Pharmaceuticals Appoints Vinay Shah as Chief Financial Officer Exhibit 99.1 Adial Pharmaceuticals Appoints Vinay Shah as Chief Financial Officer Glen Allen, VA – November 5, 2024 – Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced the appointment of Vinay Shah as the Company’s Chie |
|
| November 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 1, 2024 Adial Pharmaceuticals, Inc. (Exact name of registrant as specified in charter) Delaware (State or other jurisdiction of incorporation) 001-38323 82-3074668 (Commissio |
|
| November 5, 2024 |
Exhibit 10.2 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) is entered into as of November 16, 2024 (the “Effective Date”) by and between Adial Pharmaceuticals, Inc., a Delaware corporation, (the “Company”), and Vinay K. Shah (the “Executive”). Recitals WHEREAS, the Company desires to employ the Executive as a full-time Chief Financial Officer of the Company and the Executive de |
|
| September 30, 2024 |
2023 Annual Report to Shareholders Adial Pharmaceuticals, Inc.UNITED STATES SECURITIES AND EXCHANGE COMMISSION W ASHINGTON, DC 20549 FORM 10-K 6 ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from t |
|
| September 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6 (e)(2)) ☒ Definitive Proxy Stat |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38323 ADIAL PHARMACEUTICALS |
|
| May 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38323 ADIAL PHARMACEUTICAL |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 24, 2024 Adial Pharmaceuticals, Inc. (Exact name of registrant as specified in charter) Delaware (State or other jurisdiction of incorporation) 001-38323 82-3074668 (Commission |
|
| April 26, 2024 |
Exhibit 10.1 SEPARATION AGREEMENT AND RELEASE This Separation Agreement and Release (“Agreement”), dated April 22, 2024, is made by and between Adial Pharmaceuticals, Inc. (“Adial”, or the “Company”) and Dr. Bankole Johnson (“Consultant”) (collectively referred to as the “Parties” or individually referred to as a “Party”). RECITALS WHEREAS, Consultant was engaged by the Company pursuant to that ce |
|
| April 23, 2024 |
2,369,000 Shares Of Common Stock Filed Pursuant to Rule 424(b)(3) PROSPECTUS Registration No. 333-278652 2,369,000 Shares Of Common Stock This prospectus relates to the resale from time to time of up to an aggregate of 2,369,000 shares of common stock, par value $0.001 per share (the “common stock”), of Adial Pharmaceuticals, Inc. by the Selling Stockholders identified in this prospectus (the “Selling Stockholders”), including th |
|
| April 18, 2024 |
ADIAL PHARMACEUTICALS, INC. Up to $4,283,650 Shares of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-276496 PROSPECTUS SUPPLEMENT (To prospectus dated January 24, 2024) ADIAL PHARMACEUTICALS, INC. Up to $4,283,650 Shares of Common Stock We have entered into an At The Market Offering Agreement (the “sales agreement”), with H.C. Wainwright & Co., LLC (“Wainwright”), dated April 18, 2024, relating to the sale of our common stock, $0.001 par value |
|
| April 18, 2024 |
Exhibit 1.1 AT THE MARKET OFFERING AGREEMENT April 18, 2024 H.C. Wainwright & Co., LLC 430 Park Avenue New York, New York 10022 Ladies and Gentlemen: Adial Pharmaceuticals, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with H.C. Wainwright & Co., LLC (the “Manager”) as follows: 1. Definitions. The terms that follow, when used in this Agreement and any Term |
|
| April 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 18, 2024 Adial Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-38323 82-3074668 (State or other jurisdiction of Incorporation or organi |
|
| April 17, 2024 |
April 17, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| April 17, 2024 |
United States securities and exchange commission logo April 17, 2024 Cary Claiborne Chief Executive Officer Adial Pharmaceuticals, Inc. |
|
| April 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 10, 2024 Adial Pharmaceuticals, Inc. (Exact name of registrant as specified in charter) Delaware (State or other jurisdiction of incorporation) 001-38323 82-3074668 (Commission |
|
| April 12, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Adial Pharmaceuticals, Inc. |
|
| April 12, 2024 |
As filed with the Securities and Exchange Commission on April 12, 2024. As filed with the Securities and Exchange Commission on April 12, 2024. Registration Statement No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ADIAL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 8071 82-3074668 (State or other jurisdiction of incorporation or or |
|
| April 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38323 ADIAL PHARMACEUTICALS, INC. |
|
| April 1, 2024 |
Exhibit 21.1 List of Subsidiaries of Adial Pharmaceuticals, Inc. Purnovate, Inc., a Delaware corporation |
|
| April 1, 2024 |
Exhibit 97.1 Adial Pharmaceuticals, Inc. Clawback Policy The Board of Directors (the “Board”) of Adial Pharmaceuticals, Inc. (the “Company”) has determined that it is in the best interests of the Company to adopt this Clawback Policy (this “Policy”), which provides for the recovery of certain incentive compensation in the event of an Accounting Restatement (as defined below). This Policy is design |
|
| March 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 1, 2024 Adial Pharmaceuticals, Inc. (Exact name of registrant as specified in charter) Delaware 001-38323 82-3074668 (State or other jurisdiction of incorporation) (Commission F |
|
| March 6, 2024 |
Exhibit 10.1 ADIAL PHARMACEUTICALS, INC. March 1, 2024 Holder of Common Stock Purchase Warrants Re: Inducement Offer to Exercise Common Stock Purchase Warrants Dear Holder: Adial Pharmaceuticals, Inc. (the “Company”) is pleased to offer to you (“Holder”, “you” or similar terminology) the opportunity to receive new warrants to purchase shares of the Company’s common stock, par value $0.001 per shar |
|
| March 6, 2024 |
Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| March 6, 2024 |
Adial Pharmaceuticals Announces Exercise of Warrants for $3.5 Million Gross Proceeds Exhibit 99.1 Adial Pharmaceuticals Announces Exercise of Warrants for $3.5 Million Gross Proceeds CHARLOTTESVILLE, VA / ACCESSWIRE / March 1, 2024 / Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced the entry into a def |
|
| March 6, 2024 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| February 14, 2024 |
US00688A2050 / ADIAL PHARMACEUTICALS INC / ARMISTICE CAPITAL, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| January 25, 2024 |
$100,000,000 ADIAL PHARMACEUTICALS, INC. Common Stock Preferred Stock Debt Securities Filed Pursuant to Rule 424(b)(5) Registration No. 333-276496 PROSPECTUS $100,000,000 ADIAL PHARMACEUTICALS, INC. Common Stock Preferred Stock Debt Securities Warrants Units We may, from time to time, offer and sell up to $100,000,000 of any combination of our common stock, par value $0.001 (the “common stock”), preferred stock, par value $0.001 (the “preferred stock”), debt securities, warrants or |
|
| January 22, 2024 |
January 22, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| January 19, 2024 |
United States securities and exchange commission logo January 19, 2024 Joseph Truluck Chief Financial Officer Adial Pharmaceuticals, Inc. |
|
| January 18, 2024 |
Exhibit 10.2 Attachment “A” Statement of Work #2 This Statement of Work #2 dated January 17, 2024 (this “SOW#2”) and all services performed hereunder shall be governed by and incorporated by reference into the terms and conditions of that certain Master Services Agreement and SOW#1 dated March 15, 2023 (collectively, the “Agreement”) between Adial Pharmaceuticals, Inc. (“Company”) and The Keswick |
|
| January 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): January 17, 2024 Adial Pharmaceuticals, Inc. (Exact name of registrant as specified in charter) Delaware 001-38323 82-3074668 (State or other jurisdiction of incorporation) (Commissio |
|
| January 18, 2024 |
Exhibit 99.1 Adial Announces Appointment of Tony Goodman as Chief Operating Officer Highly Experienced Pharma Commercial and Business Development Executive in Addiction Treatment Space Joins Leadership Team While Continuing as Board Member Charlottesville, VA, – Jan. xx, 2024 – Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company |
|
| January 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): January 11, 2024 Adial Pharmaceuticals, Inc. (Exact name of registrant as specified in charter) Delaware (State or other jurisdiction of incorporation) 001-38323 82-3074668 (Commissio |
|
| January 12, 2024 |
As filed with the Securities and Exchange Commission on January 12, 2024 As filed with the Securities and Exchange Commission on January 12, 2024 Registration Statement No. |
|
| January 12, 2024 |
Exhibit 4.3 ADIAL PHARMACEUTICALS, INC. Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of , 20 Debt Securities TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee’s Certificate 6 Sec |
|
| January 12, 2024 |
Calculation of Filing Fee Table Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Adial Pharmaceuticals, Inc. |
|
| December 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6 (e)(2)) ☐ Definitive Proxy Stat |
|
| December 12, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Adial Pharmaceuticals, Inc. |
|
| December 12, 2023 |
As filed with the Securities and Exchange Commission on December 12, 2023 As filed with the Securities and Exchange Commission on December 12, 2023 Registration No. |
|
| December 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6 (e)(2)) ☒ Definitive Proxy Stat |
|
| November 29, 2023 |
Adial Pharmaceuticals Regains Compliance with Nasdaq Listing Requirement Exhibit 99.1 Adial Pharmaceuticals Regains Compliance with Nasdaq Listing Requirement Charlottesville, VA – November 29, 2023 – Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it received notice from Nasda |
|
| November 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 29, 2023 Adial Pharmaceuticals, Inc. (Exact name of registrant as specified in charter) Delaware 001-38323 82-3074668 (State or other jurisdiction of incorporation) (Commissi |
|
| November 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 21, 2023 Adial Pharmaceuticals, Inc. (Exact name of registrant as specified in charter) Delaware 001-38323 82-3074668 (State or other jurisdiction of incorporation) (Commissi |
|
| November 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6 (e)(2)) ☐ Definitive Proxy Stat |
|
| November 20, 2023 |
PROSPECTUS Filed Pursuant to Rule 424(b)(3) Registration No. 333-275397 4,340,426 Shares Common Stock This prospectus relates to the resale from time to time of up to 4,340,426 shares of Common Stock, par value $0.001 per share (the “Common Stock”), of Adial Pharmaceuticals, Inc. by the selling stockholders identified in this prospectus (the “Selling Stockholders”), including their pledgees, assig |
|
| November 15, 2023 |
November 15, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| November 14, 2023 |
United States securities and exchange commission logo November 14, 2023 Cary Claiborne President and Chief Executive Officer Adial Pharmaceuticals, Inc. |
|
| November 14, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 14, 2023 Adial Pharmaceuticals, Inc. (Exact name of registrant as specified in charter) Delaware 001-38323 82-3074668 (State or other jurisdiction of incorporation) (Commissi |
|
| November 14, 2023 |
Exhibit 99.1 Adial Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update Advancing Discussions with Potential Strategic Partners Received Frost & Sullivan’s 2023 North American Precision Medicine for Addiction Disorders Technology Innovation Leadership Award Closed $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules; Extends Cash Runway into Q4 |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38323 ADIAL PHARMACEUT |
|
| November 8, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Adial Pharmaceuticals, Inc. |
|
| November 8, 2023 |
As filed with the Securities and Exchange Commission on November 8, 2023. As filed with the Securities and Exchange Commission on November 8, 2023. Registration Statement No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ADIAL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 8071 82-3074668 (State or other jurisdiction of incorporation or |
|
| November 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 2, 2023 Adial Pharmaceuticals, Inc. (Exact name of registrant as specified in charter) Delaware (State or other jurisdiction of incorporation) 001-38323 82-3074668 (Commissio |
|
| November 6, 2023 |
Exhibit 10.1 AMENDMENT NO. 5 TO THE ADIAL PHARMACEUTICALS, INC. 2017 EQUITY INCENTIVE PLAN This amendment (the “Amendment”) to the Adial Pharmaceuticals, Inc. 2017 Equity Incentive Plan (the “Plan”), is hereby adopted as of September 29, 2023, by the Board of Directors (the “Board”) of Adial Pharmaceuticals, Inc. (the “Company”). All capitalized terms used in this Amendment and not otherwise defin |
|
| October 30, 2023 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12B-25/A AMENDMENT NO. 1 NOTIFICATION OF LATE FILING SEC FILE NUMBER 001-38323 CUSIP NUMBER 00688A 205 (Check One): ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K ☒ Form 10-Q ¨ Form 10-D ¨ Form N-CEN ¨ Form N-CSR For Period Ended: June 30, 2023 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K |
|
| October 30, 2023 |
Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A Amendment No. 1 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 17, 2023 Adial Pharmaceuticals, Inc. (Exact name of registrant as specified in charter) Delaware 001-38323 82-3074668 (State or other jurisdiction of incorpor |
|
| October 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A AMENDMENT NO.1 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38323 ADIA |
|
| October 24, 2023 |
Exhibit 4.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| October 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): October 19, 2023 Adial Pharmaceuticals, Inc. (Exact name of registrant as specified in charter) Delaware 001-38323 82-3074668 (State or other jurisdiction of incorporation) (Commissio |
|
| October 24, 2023 |
Adial Pharmaceuticals Announces $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Exhibit 99.1 Adial Pharmaceuticals Announces $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules CHARLOTTESVILLE, VA, October 20, 2023 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it has ente |
|
| October 24, 2023 |
Exhibit 99.2 Adial Pharmaceuticals Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules CHARLOTTESVILLE, VA, October 24, 2023 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that |
|
| October 24, 2023 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| October 24, 2023 |
Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| October 24, 2023 |
Exhibit 4.4 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| October 24, 2023 |
Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of October 19, 2023, by and between Adial Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). This Agreement is made pursuant to the Secur |
|
| October 24, 2023 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of October 19, 2023, between Adial Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and cond |
|
| October 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6 (e)(2)) ☒ Definitive Proxy Stat |
|
| October 2, 2023 |
2022 Annual Report to Shareholders Adial Pharmaceuticals, Inc.UNITED STATES SECURITIES AND EXCHANGE COMMISSION W ASHINGTON, DC 20549 FORM 10-K 6 ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from t |
|
| September 27, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): September 26, 2023 Adial Pharmaceuticals, Inc. (Exact name of registrant as specified in charter) Delaware 001-38323 82-3074668 (State or other jurisdiction of incorporation) (Commiss |
|
| September 27, 2023 |
ADIAL PHARMACEUTICALS, INC. FINANCIAL STATEMENTS Exhibit 99.1 Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations. The following discussion and analysis is intended as a review of significant factors affecting our financial condition and results of operations for the periods indicated. The discussion should be read in conjunction with our consolidated financial statements and the notes presented herein. |
|
| September 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): September 18, 2023 Adial Pharmaceuticals, Inc. (Exact name of registrant as specified in charter) Delaware 001-38323 82-3074668 (State or other jurisdiction of incorporation) (Commiss |
|
| September 21, 2023 |
Exhibit 2.3 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS EXHIBIT MARKED BY [***] HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL FINAL ACQUISITION AGREEMENT This Final Acquisition Agreement, dated as of September 18, 2023 (this “Agreement”), is a legally binding agreement to memorialize the sale by PURNOVAT |
|
| September 11, 2023 |
Exhibit 99.1 December 2021 CONFIDENTIAL Medicines f or A ddi c tion H.C. Wainwright Global Investment Conference September 11, 2023 CONFIDENTIAL This presentation includes statements that are, or may be deemed, ‘‘forward - looking statements.’’ In some cases, these forward - l ooking statements can be identified by the use of forward - looking terminology, including the terms “believes,” “might,” |
|
| September 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): September 11, 2023 Adial Pharmaceuticals, Inc. (Exact name of registrant as specified in charter) Delaware 001-38323 82-3074668 (State or other jurisdiction of incorporation) (Commiss |
|
| August 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 21, 2023 Adial Pharmaceuticals, Inc. (Exact name of registrant as specified in charter) Delaware 001-38323 82-3074668 (State or other jurisdiction of incorporation) (Commission |
|
| August 23, 2023 |
Adial Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements Exhibit 99.1 Adial Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements Charlottesville, VA – August 23, 2023 – Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it received notice from Nasdaq |
|
| August 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 21, 2023 Adial Pharmaceuticals, Inc. (Exact name of registrant as specified in charter) Delaware 001-38323 82-3074668 (State or other jurisdiction of incorporation) (Commission |
|
| August 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38323 ADIAL PHARMACEUTICALS |
|
| August 21, 2023 |
Exhibit 99.1 Adial Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update Reported Positive Feedback from US and EU Regulatory Meetings Sale of Purnovate Significantly Reduces Cash Burn Rate Charlottesville, VA – August 21, 2023 – Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on d |
|
| August 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 30, 2023 Adial Pharmaceuticals, Inc. (Exact name of registrant as specified in charter) Delaware 001-38323 82-3074668 (State or other jurisdiction of incorporation) (Commission F |
|
| August 18, 2023 |
UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL INFORMATION Exhibit 99.1 UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL INFORMATION The following unaudited pro forma condensed consolidated balance sheet and statements of operations are based upon the historical consolidated financial statements of Adial Pharmaceuticals, Inc. (the “Company”). Unless the context indicates otherwise, any reference in this report to the “Company,” “we,” “us,” and “our” r |
|
| August 15, 2023 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12B-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 001-38323 CUSIP NUMBER 00688A 205 (Check One): ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K ☒ Form 10-Q ¨ Form 10-D ¨ Form N-CEN ¨ Form N-CSR For Period Ended: June 30, 2023 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Transition Repo |
|
| August 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 3, 2023 Adial Pharmaceuticals, Inc. (Exact name of registrant as specified in charter) Delaware 001-38323 82-3074668 (State or other jurisdiction of incorporation) (Commission |
|
| August 4, 2023 |
Exhibit 99.1 Adial Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid Price Requirement and Reduce the Public Float Common Stock Will Begin Trading on Split-Adjusted Basis on August 7, 2023 Charlottesville, VA – August 4, 2023 – Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused |
|
| August 4, 2023 |
Exhibit 3.1 State of Delaware Secretary of State Division of Corporations Delivered 08:03 AM 08/03/2023 FILED 08:03 AM 08/03/2023 SR 20233153666 - File Number 6439279 CERTIFICATE OF AMENDMENT OF CERTIFICATE OF INCORPORATION OF ADIAL PHARMACEUTICALS, INC. Adial Pharmaceuticals, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the S |
|
| July 31, 2023 |
Up to 1,740,990 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) PROSPECTUS Registration No. 333-272846 Up to 1,740,990 Shares of Common Stock This prospectus relates to the offering and resale by Alumni Capital LP (“Alumni Capital” or the “Selling Stockholder”) of up to 1,740,990 shares (the “Shares”) of our common stock, par value $0.001 per share, which includes 199,620 shares of our common stock issued to the Selling Stockho |
|
| July 25, 2023 |
July 25, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| July 13, 2023 |
1271 Avenue of the Americas | New York, New York 10020 Blankrome.com July 13, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Cindy Polynice Re: Adial Pharmaceuticals, Inc. Registration Statement on Form S-1 Filed June 23, 2023 File No. 333-272846 Dear Ms. Polynice: On behalf of our client, Adial P |
|
| July 13, 2023 |
As filed with the Securities and Exchange Commission on July 13, 2023 As filed with the Securities and Exchange Commission on July 13, 2023 Registration No. |
|
| July 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 7, 2023 Adial Pharmaceuticals, Inc. (Exact name of registrant as specified in charter) Delaware 001-38323 82-3074668 (State or other jurisdiction of incorporation) (Commission Fi |
|
| July 7, 2023 |
United States securities and exchange commission logo July 7, 2023 Cary Claiborne President and Chief Executive Officer Adial Pharmaceuticals, Inc. |
|
| June 23, 2023 |
As filed with the Securities and Exchange Commission on June 22, 2023 As filed with the Securities and Exchange Commission on June 22, 2023 Registration No. |
|
| June 23, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-1 (Form Type) Adial Pharmaceuticals, Inc. |
|
| June 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 9, 2023 Adial Pharmaceuticals, Inc. (Exact name of registrant as specified in charter) Delaware (State or other jurisdiction of incorporation) 001-38323 82-3074668 (Commission Fi |
|
| June 9, 2023 |
Exhibit 99.1 December 2021 CONFIDENTIAL Medicines f or A ddi c tion June 9, 2023 CONFIDENTIAL Jefferies Healthcare Conference This presentation includes statements that are, or may be deemed, ‘‘forward - looking statements.’’ In some cases, these forward - looking statements can be identified by the use of forward - looking terminology, including the terms “believes,” “might,” estimates,” “approxi |
|
| June 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 31, 2023 Adial Pharmaceuticals, Inc. (Exact name of registrant as specified in charter) Delaware 001-38323 82-3074668 (State or other jurisdiction of incorporation) (Commission Fi |
|
| June 2, 2023 |
Exhibit 10.1 PURCHASE AGREEMENT PURCHASE AGREEMENT (the “Agreement”), dated as of May 31, 2023, by and between ADIAL PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and ALUMNI CAPITAL LP, a Delaware limited partnership (the “Investor”). RECITALS WHEREAS, Subject to the terms and conditions set forth in this Agreement, the Company wishes to sell to the Investor, and the Investor wish |
|
| May 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 19, 2023 Adial Pharmaceuticals, Inc. (Exact name of registrant as specified in charter) Delaware 001-38323 82-3074668 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 12, 2023 Adial Pharmaceuticals, Inc. (Exact name of registrant as specified in charter) Delaware 001-38323 82-3074668 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 12, 2023 |
Exhibit 99.1 Adial Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update Conducted meetings with U.S. and select European regulatory agencies Received Notice of Exercise and upfront cash of $0.45 million from Advocate for the sale of Purnovate assets and business Ended 2023 first quarter with cash and cash equivalents of $2.3 million Charlottesville, VA – May 12 |
|
| May 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38323 ADIAL PHARMACEUTICAL |
|
| May 10, 2023 |
Exhibit 2.2 1180 Seminole Tr., Suite 495 Charlottesville, VA 22901 +1 (434) 202-2525 www.adenomed.com May 8, 2023 Cary Claiborne Chief Executive Officer Adial Pharmaceuticals, Inc. 1180 Seminole Tr., Ste. 495 Charlottesville, VA 22901 RE: Notice of Option Exercise Dear Mr. Claiborne, Reference is made to that certain Option Agreement to acquire the business of Purnovate, Inc. (“Option Agreement”), |
|
| May 10, 2023 |
Exhibit 99.1 Adial Pharmaceuticals Receives Notice of Exercise from Adovate for the Acquisition of Purnovate’s Assets and Business Adial to receive potential development and commercial milestone payments of up to $83 million on the first three compounds plus 19.9% equity stake and ongoing royalties Charlottesville, VA – May 10, 2023 – Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or t |
|
| May 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 8, 2023 Adial Pharmaceuticals, Inc. (Exact name of registrant as specified in charter) Delaware 001-38323 82-3074668 (State or other jurisdiction of incorporation) (Commission Fil |
|
| April 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 12, 2023 Adial Pharmaceuticals, Inc. (Exact name of registrant as specified in charter) Delaware (State or other jurisdiction of incorporation) 001-38323 82-3074668 (Commission |
|
| March 31, 2023 |
Exhibit 99.1 Adial Pharmaceuticals Reports 2022 Fiscal Year Financial Results and Provides Business Update Secured meetings with U.S. and European regulatory agencies Advancing partnership activities in both the U.S. and Europe Ended 2022 fiscal year with cash and cash equivalents of $4.0 million Charlottesville, VA – March 30, 2023 – Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or t |
|
| March 31, 2023 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 30, 2023 Adial Pharmaceuticals, Inc. (Exact name of registrant as specified in charter) Delaware (State or other jurisdiction of incorporation) 001-38323 82-3074668 (Commission |
|
| March 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38323 ADIAL PHARMACEUTICALS, INC. |
|
| March 30, 2023 |
Exhibit 21.1 List of Subsidiaries of Adial Pharmaceuticals, Inc. Purnovate, Inc., a Delaware corporation |
|
| March 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| March 21, 2023 |
Exhibit 99.1 Adial Pharmaceuticals Engages The Keswick Group to Advance Partnering Activities for the Clinical Development of AD04 for Alcohol Use Disorder The Keswick Group is led by experienced pharmaceutical business development executive, Tony Goodman Charlottesville, VA, March 21, 2023 – Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmace |
|
| March 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 15, 2023 Adial Pharmaceuticals, Inc. (Exact name of registrant as specified in charter) Delaware 001-38323 82-3074668 (State or other jurisdiction of incorporation) (Commission |
|
| March 21, 2023 |
Exhibit 10.1 MASTER SERVICES AGREEMENT This Services Agreement (this “Agreement”) is entered into effective March 15, 2023 (the “Effective Date”) by and between Adial Pharmaceuticals, Inc., a Delaware corporation with a business address at 1180 Seminole Trail, Suite 495, Charlottesville, VA 22901-5739 and its subsidiaries and affiliates (collectively, “Company”), and The Keswick Group, LLC, with a |
|
| March 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 6, 2023 Adial Pharmaceuticals, Inc. (Exact name of registrant as specified in charter) Delaware (State or other jurisdiction of incorporation) 001-38323 82-3074668 (Commission F |
|
| March 7, 2023 |
Exhibit 99.2 December 2021 CONFIDENTIAL AD04 Business Update March 7, 2023 CONFIDENTIAL Recent History • Results from the Phase 3 ONWARD trial were released in July 2022. The trial missed its primary endpoint. • The trial showed statistical significance in a pre - defined patient group, which created an opportunity to course correct. • After further analyzing the clinical data, we found specific p |
|
| March 7, 2023 |
Exhibit 99.1 Adial Pharmaceuticals Provides Update on Regulatory Strategy for AD04 for Treatment of Alcohol Use Disorder Company to pursue path toward U.S. and European approvals; Type C meeting with FDA confirmed for Q2 2023; plans in place to meet with multiple European regulatory authorities Adial in discussions with potential pharma partners Conference call to be held at 8:15 a.m. EST tomorrow |
|
| March 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| March 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 28, 2023 Adial Pharmaceuticals, Inc. (Exact name of registrant as specified in charter) Delaware (State or other jurisdiction of incorporation) 001-38323 82-3074668 (Commissi |
|
| February 27, 2023 |
Adial Pharmaceuticals Announces Closing of $0.75 Million At-The-Market Registered Direct Offering Exhibit 99.1 Adial Pharmaceuticals Announces Closing of $0.75 Million At-The-Market Registered Direct Offering Charlottesville, VA, Feb. 27, 2023 – Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced the closing of |
